This trial is a prospective, single-arm, multi-center clinical trial. Four hospitals with national medical trial institution qualifications are selected as clinical trial centers. Qualified participants will receive endoscopic ultrasound-guided laser ablation by LaserPro Diode Laser System according to the routine procedures. The results will be recorded according to the requirements of the primary and secondary efficacy indicators. After then, statistical comparisons of effectiveness and safety of the procedure will be made according to groups.
The prospective, single-arm, multi-center clinical trial is to evaluate whether the endoscopic ultrasound (EUS)-guided laser ablation (LA) by LaserPro Diode Laser System can achieve the safety and effectivenessof liver cancer ablation treatment. Four hospitals with national medical clinical trial institution qualifications are selected as clinical trial centers. This clinical trial requires 69 subjects. Qualified participants will receive EUS-guided LA by LaserPro Diode Laser System according to the routine procedures. The results will be recorded according to the requirements of the primary outcome (the complete ablation (CA) rate and the effective rate of EUS-guided LA by LaserPro Diode Laser System for liver cancer) and secondary outcomes (technical success rate, major complication rate, partial response rate, secondary ablation rate, progression-free survival (PFS), overall survival rate (OS), local tumor progression (LTP), distant tumor recurrence (DTR), quality of life score and alpha-fetoprotein levels). The one-month follow-up after the operation, three-phase MRI, liver function and tumor markers were reviewed monthly to observe the lesion necrosis and tumor marker changes. After that, tumor markers, three-phase MRI of liver were examined every 2 to 3 months. After then, statistical comparisons of safety and effectivenessof the producedure will be made according to groups.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
69
This trial is a prospective, single-arm, multi-center clinical trial. Four hospitals with national medical trial institution qualifications are selected as clinical trial centers. Qualified participants will receive endoscopic ultrasound (EUS)-guided laser ablation (LA) by LaserPro Diode Laser System according to the routine procedures. The results will be recorded according to the requirements of the primary and secondary efficacy indicators. After then, statistical comparisons of effectiveness and safety of the procedure will be made according to groups.
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Complete ablation rate
Defined as the absence of any contrast uptake within or at the periphery of the ablative zone. One month after either one session or multiple LA sessions, CTA was confirmed by contrast-enhanced MRI.
Time frame: 1 month
Effectiveness analysis
The effective rate of EUS-LA by LaserPro Diode Laser System for liver cancer was evaluated by mRECIST criteria.
Time frame: 6 months
Technical success rate
Technical success rate of EUS-LA by LaserPro Diode Laser System for liver cancer.
Time frame: 1 month
Major complication rate
Major complication rate after EUS-LA by LaserPro Diode Laser System for liver cancer.
Time frame: 6 months
Partial response rate
Partial response rate after EUS-LA by LaserPro Diode Laser System for liver cancer.
Time frame: 6 months
Secondary ablation rate
Secondary ablation rate after EUS-LA by LaserPro Diode Laser System for liver cancer.
Time frame: 6 months
Progression-free survival (PFS)
Progression-free survival after EUS-LA by LaserPro Diode Laser System for liver cancer.
Time frame: 6 months
Overall survival rate (OS)
Overall survival rate after EUS-LA by LaserPro Diode Laser System for liver cancer.
Time frame: 6 months
Local tumor progression (LTP)
Local tumor progression after EUS-LA by LaserPro Diode Laser System for liver cancer.
Time frame: 6 months
Distant tumor recurrence (DTR)
Distant tumor recurrence after EUS-LA by LaserPro Diode Laser System for liver cancer.
Time frame: 6 months
Quality of life score
Quality of life score of participants after EUS-LA by LaserPro Diode Laser System for liver cancer.
Time frame: 6 months
Alpha-fetoprotein levels
The alpha-fetoprotein levels of participants after EUS-LA by LaserPro Diode Laser System for liver cancer.
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.